Cerebrospinal fluid amyloid β1-42 levels in the mild cognitive impairment stage of Alzheimer's disease

Experimental Neurology

Volumn 172, Issue 2, 2001, Pages 433-436

  Maruyama, Masahiro ^a   Arai, Hiroyuki ^a   Sugita, Mitsunori ^b   Tanji, Haruko ^a   Higuchi, Makoto ^a   Okamura, Nobuyuki ^a   Matsui, Toshifumi ^a   Higuchi, Susumu ^c   Matsushita, Sachio ^c   Yoshida, Hiroshi ^b   Sasaki, Hidetada ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Nissho Corporation   (Japan)

^c KURIHAMA NATIONAL HOSPITAL   (Japan)

Author keywords

Alzheimer's disease; Amyloid protein; Biomarker; Cerebrospinal fluid; Mild cognitive impairment; Tau

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; ENZYME IMMUNOASSAY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; QUANTITATIVE ASSAY; RISK ASSESSMENT;

EID: 0035693097     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.2001.7814     Document Type: Article

References (17)

1. Mild cognitive impairment. An early stage of Alzheimer's disease?
2. Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment
3. Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease
4. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease
5. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease
6. Cerebrospinal fluid Aβ42 is increased early in sporadic Alzheimer's disease and declines with disease progression
7. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under auspices of the Department of Health and Human Services Task Force on Alzheimer's disease
8. Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline
9. 1-42, but not tau have positive correlation with brain glucose metabolism in humans
10. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals
11. Mild cognitive impairment: Clinical characterization and outcome
12. Cerebrospinal fluid tau is elevated in early Alzheimer's disease
13. Elevated cerebrospinal fluid tau: Implications for early diagnosis of Alzheimer's disease
14. Consensus report of the working group on molecular and biochemical markers of Alzheimer's disease
15. Prediction of probable Alzheimer's disease in memory-impaired patients: A prospective longitudinal study
16. Development of a specific diagnostic test for measurement of β-amyloid 1-42 in CSF